Develops targeted cancer therapies focusing on cell cycle regulation.
Cyclacel Pharmaceuticals, Inc., headquartered in Berkeley Heights, New Jersey, is a clinical-stage biopharmaceutical company specializing in the development of therapies for cancer and other proliferative diseases. The company's robust pipeline includes innovative candidates designed to target various forms of cancer and advance treatment options.
Leading the development efforts is fadraciclib, a cyclin-dependent kinase inhibitor (CDK) currently in Phase 1/2 clinical trials for solid tumors. This compound is also being investigated in combination with venetoclax for relapsed or refractory chronic lymphocytic leukemia. Additionally, Cyclacel is advancing CYC140, a polo-like kinase inhibitor program, through Phase 1/2 clinical trials aimed at treating advanced leukemias and solid tumors.
Among its diverse portfolio, Cyclacel is exploring sapacitabine, an orally available prodrug of CNDAC, a novel nucleoside analog. This compound is undergoing Phase 1/2 clinical trials for acute myeloid leukemia and myelodysplastic syndrome. The company also continues to evaluate seliciclib, another CDK inhibitor, in Phase 2 investigator-sponsored trials for Cushing's disease and Phase 1/2 trials for advanced rheumatoid arthritis. Cyclacel Pharmaceuticals collaborates closely with the University of Texas MD Anderson Cancer Center to further explore the safety and efficacy of its therapies across hematological malignancies.
With a commitment to advancing oncology treatments, Cyclacel Pharmaceuticals remains dedicated to pioneering therapies that target critical pathways in cancer biology, aiming to improve outcomes for patients worldwide.